The clinical application of camrelizumab on advanced hepatocellular carcinoma

Chen, Zhongguang; Lu, Xiuhua; Koral, Kelly

doi:10.1080/17474124.2020.1807939

Cited by 19 publications

(21 citation statements)

References 53 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Only 341 publications were published in the top ten academic journals, accounting for only 20.78% of all articles. Cancer Immunology Immunotherapy ( 30 ) ranked first in terms of total publications, followed by Oncoimmunology ( 30 ) and Oncotarget ( 31 ), indicating that these journals were particularly interested in articles regarding HCC immunotherapy research. These data will aid future scientists in selecting journals when submitting HCC immunotherapy-related manuscripts.…”

Section: Discussionmentioning

confidence: 99%

“…Camrelizumab is one of the most representative drugs. Catilizumab was approved as a second-line drug for the systematic treatment of liver cancer by the National Medical Products Administration (NMPA) in 2020 based on the findings of various clinical trials ( 31 ). This adds a new treatment option to the treatment options for patients with advanced liver cancer.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Knowledge Mapping of Immunotherapy for Hepatocellular Carcinoma: A Bibliometric Study

Shen

et al. 2022

Front. Immunol.

View full text Add to dashboard Cite

BackgroundHepatocellular carcinoma (HCC) is one of the most common malignant tumors, and many patients are diagnosed with advanced disease. The treatment of advanced liver cancer has made significant strides in recent years, owing to the practice of immunotherapy drugs. Numerous studies have been published on immunotherapy for HCC; however, no relevant bibliometric study has been published. This study aims to gain a better understanding of the current situation and to identify potential new research directions by conducting a bibliometric analysis on immunotherapy for HCC.MethodsWe searched the Web of Science Core Collection (WoSCC) for articles related to immunotherapy for HCC. Three software (VOSviewer, CiteSpace, and python) were primarily used to assess the contribution and co-occurrence relationships of various countries/regions, institutes, journals, and, authors as well as to identify research hotspots and promising future trends in this research field.ResultsA total of 1,641 English articles published between 2011 and 2020 were collected, with the number of articles increasing nearly every year. The majority of publications originated from China (n = 893, 54.42%), followed by the United States and Japan. The Sun Yat-sen University contributed the most publications (n = 97, 5.91%). Nakatsura Tetsuya (n = 26) and Llovet JM (n = 366) were ranked first in the top ten authors and co-cited authors. Cancer Immunology Immunotherapy was the most productive academic journal on immunotherapy for HCC [n = 46, 2.80%; impact factor (IF) 2020 = 6.9679]. Aggregation and identification of critical nodes in the co-cited network demonstrated a shift in the field of HCC immunotherapy. Initially, the hotspots were predominantly “glypican-3”, “cytokine-induced killer cells”, and “ny-eso-1”, while the emphasis has shifted in recent years to “landscape”, “camrelizumab”, “combination therapy”, and “immune score”.ConclusionIncreased attention has been paid to HCC with the advancement of immunotherapy. At the moment, the most active frontiers are focused on better understanding the immunological landscape of liver cancer, screening the population that can benefit from immunotherapy, and the clinical application of immune checkpoint inhibitors, particularly in combination with other therapeutic options (such as local therapy and targeted therapy).

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Knowledge Mapping of Immunotherapy for Hepatocellular Carcinoma: A Bibliometric Study

Shen

et al. 2022

Front. Immunol.

View full text Add to dashboard Cite

show abstract

“…The indication was the treatment of patients with relapsed or refractory classical HDL who had received at least second-line systemic chemotherapy (12). In 2020, it was approved for the treatment of patients with advanced HCC who had previously received sorafenib treatment and/or oxaliplatin containing systemic chemotherapy, combination of pemetrexed, and carboplatin for the first-line treatment of unresectable locally advanced or metastatic NSCLC with negative epidermal growth factor receptor (EGFR) gene mutation and negative anaplastic lymphoma kinase (ALK), and for the treatment of patients with locally advanced or metastatic ES who had previously received first-line chemotherapy (22,23). In 2020, camrelizumab was recommended by the Chinese Society of Clinical Oncology (CSCO) clinical guidelines for the treatment of NSCLC, HCC, EC, and HDL and became the only immunotherapy drug to achieve this achievement in China (24).…”

Section: Discussionmentioning

confidence: 99%

Efficacy and Safety of Camrelizumab Monotherapy and Combination Therapy for Cancers: A Systematic Review and Meta-Analysis

Wang

et al. 2021

Front. Oncol.

View full text Add to dashboard Cite

ObjectiveThis meta-analysis compared the safety and efficacy of camrelizumab monotherapy and combination therapy, aiming to provide a reference for the clinical combined use of camrelizumab in the treatment of cancers and also provide a reference for the development of subsequent indications of camrelizumab.MethodsMeta-analysis was used to analyze the four eligible literatures. Primary endpoints of effectiveness index were objective response rate (ORR), progression-free survival (PFS), control rate (CR). Primary endpoint of safety index was rating of severity of adverse drug reactions (grades 1–5).ResultsThe ORR, PFS, and CR values of combined treatment with camrelizumab was better than alone treatment, camrelizumab alone was better than chemotherapy (RR = 0.45; 95% CI, 0.30–0.67; P < 0.001; RR = 1.63; 95% CI, 1.25–2.13; P < 0.001; RR = 0.73; 95% CI, 0.52–1.02; P<0.001). When grade > 2, the incidence rate of combined treatment and chemotherapy are higher than monotherapy (RR = 0.66; 95% CI, 0.51–0.86; P<0.001). In any grade, the safety of camrelizumab combination therapy was better than that of monotherapy, the safety of chemotherapy was better than camrelizumab plus chemotherapy.ConclusionIn terms of effectiveness, the combination of camrelizumab is better than monotherapy, and monotherapy is better than chemotherapy. In terms of safety, when the grade > 2, single use is better than combination therapy and chemotherapy. In any grade of adverse event, the safety of combined use of camrelizumab is better than that of single use, and the safety of chemotherapy is better than the combined use of camrelizumab plus chemotherapy.

show abstract

“…Additionally, the regimen of second-line treatment was not mentioned in the CameL trial, so we assumed that patients accepted docetaxel after PD, which was recommended in the NCCN [13]. Reactive cutaneous capillary endothelial proliferation (RCCEP) is the most common immune-related dermatologic toxicity of camrelizumab according to the CameL trial, however, the cost of treating RCCEP was excluded from our study because its effects are mild, reversible, and predictable [29].…”

Section: Discussionmentioning

confidence: 99%

“…Despite the high price of camrelizumab in China, it still shows promising tumor response in multiple tumor types with manageable toxicities [25][26][27][28][29]. The incidence of treatment-related AEs of any grade was higher in the CC group than in the CA group.…”

Section: Discussionmentioning

confidence: 99%

Camrelizumab In Patients With Advanced Non-Squamous Non-Small-Cell Lung Cancer: A Cost-Effective Analysis In China

Xie

Zheng

et al. 2021

Preprint

View full text Add to dashboard Cite

Background Camrelizumab is a selective, humanized, high-affinity IgG4 kappa monoclonal antibody against programmed cell death 1 (PD-1) that shows effective antitumor activity with acceptable toxicity in multiple tumor types. The CameL trial demonstrated that camrelizumab plus chemotherapy significantly prolonged the median progression-free survival (PFS) and median overall survival (OS) versus chemotherapy alone in patients with advanced non-squamous non-small-cell lung cancer (NSCLC). Because of a rapid cancer burden increase in China, our study was conducted to investigate the cost-effectiveness of the two strategies in chemotherapy-naive patients with advanced non-squamous NSCLC.Methods A Markov simulation model was generated based on the CameL trial. The two simulated treatments included camrelizumab plus chemotherapy (CC) and chemotherapy alone (CA). Utility was derived from published literature, and costs were calculated based on those at our hospital in Chengdu, China. Incremental cost-effectiveness ratios (ICERs) were calculated to compare the cost-effectiveness of the two treatment arms.Results The total costs were $64,874.51 and $13,531.38 for CC and CA treatment, respectively. The CC treatment produced 1.19 quality-adjusted life years (QALYs), and the CA treatment produced 0.96 QALYs. Hence, patients who were in the CC group spent an additional $51,343.44 and generated an increase of 0.23 QALYs, resulting in an ICER of $223,232.35 per QALY. Currently, in China, CC treatment is not cost-effective when considering a willingness-to-pay (WTP) threshold of $28,130 per QALY gained.Conclusions For chemotherapy-naive patients with advanced non-squamous NSCLC, camrelizumab plus chemotherapy is not considered a cost-effective therapy versus chemotherapy alone in China.

show abstract

The clinical application of camrelizumab on advanced hepatocellular carcinoma

Cited by 19 publications

References 53 publications

Knowledge Mapping of Immunotherapy for Hepatocellular Carcinoma: A Bibliometric Study

Knowledge Mapping of Immunotherapy for Hepatocellular Carcinoma: A Bibliometric Study

Efficacy and Safety of Camrelizumab Monotherapy and Combination Therapy for Cancers: A Systematic Review and Meta-Analysis

Camrelizumab In Patients With Advanced Non-Squamous Non-Small-Cell Lung Cancer: A Cost-Effective Analysis In China

Contact Info

Product

Resources

About